Emerging trends in the discovery of natural product antibacterials

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 678-687

  Bologa, Cristian G ^a,b   Ursu, Oleg ^a,b   Oprea, Tudor I ^a,b,c,d   Melançon, Charles E ^a   Tegos, George P ^a,e,f,g  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJOENE; ANSAMYCIN DERIVATIVE; ANTIINFECTIVE AGENT; BERBERINE; CETHROMYCIN; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FASAMYCIN; FIDAXOMICIN; HONAUCIN A; LINCOMYCIN; MITOMYCIN; NATURAL PRODUCT; NONRIBOSOMAL PEPTIDE SYNTHETASE; OMADACYCLINE; ORITAVANCIN; POLYKETIDE SYNTHASE; PYRIDOMYCIN; RETAPAMULIN; RIFAMPICIN; ROSEOFLAVIN; TELAVANCIN; TELITHROMYCIN; TETARIMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BIOINFORMATICS; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; SYNTHETIC BIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS;

EID: 84892992623     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.07.002     Document Type: Review

References (49)

1. Norrby SR, Nord CE, Finch R: Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 2005, 5: 115-119. (Pubitemid 40174782)
2. Haque N, Bari MS, Bilkis L, Haque S, Sultana S: Methicillin resistant Staphylococcus aureus - an overview. Mymensingh Med J 2011, 20: 159-164.
3. Cornaglia G, Giamarellou H, Rossolini GM: Metallo-b-lactamases: a last frontier for b-lactams? Lancet Infect Dis 2011, 11: 381-393.
4. Heintz BH, Halilovic J, Christensen CL: Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy 2010, 30: 1136-1149.
5. Newman DJ, Cragg GM: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75: 311-335.
6. Barrett JF: Can biotech deliver new antibiotics? Curr Opin Microbiol 2005, 8: 498-503. (Pubitemid 41355028)
7. Wright GD: Q&A: antibiotic resistance: what more do we know and what more can we do? BMC Biol 2013, 11:51.
8. Bush K, Macielag M, Weidner-Wells M: Taking inventory: antibacterial agents currently at or beyond phase 1. Curr Opin Microbiol 2004, 7: 466-476. (Pubitemid 39297126)
9. Carlson B: Combating hospital-acquired infections. Genet Eng Biotechnol News 2009, 29:18.
10. Carter GT: Natural products and pharma 2011: strategic changes spur new opportunities. Nat Prod Rep 2011, 28: 1783-1789.
11. Silver LL: Viable screening targets related to the bacterial cell wall. Ann N Y Acad Sci 2013, 1277: 29-53.
12. Kalan L, Perry J, Koteva K, Thake M, Wright G: Glycopeptide sulfation evades resistance. J Bacteriol 2013, 195: 167-171.
13. Boberek JM, Goh S, Stach J, Good L: Filamentous temperature-sensitive mutant Z (FtsZ) protein as an antibacterial target. In Antimicrobial Drug Discovery: Emerging Strategies. Edited by Tegos GP, Mylonakis E. Book Series: Advances in Molecular and Cellular Microbiology Wallingford, Oxon, UK: CABI Publishing; 2012,135-146.
14. Li Z, Garner AL, Gloeckner C, Janda KD, Carlow CK: Targeting the Wolbachia cell division protein FtsZ as a new approach for antifilarial therapy. PLoS Negl Trop Dis 2011, 5:e1411.
15. Huo L, Rachid S, Stadler M, Wenzel SC, Müller R: Synthetic biotechnology to study and engineer ribosomal bottromycin biosynthesis. Chem Biol 2012, 19: 1278-1287.
16. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet S, Mukherjee R, Uplekar S, Boy-Röttger S, Altmann KH, Cole ST: Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol Med 2012, 4: 1032-1042.
17. Pedrolli DB, Jankowitsch F, Schwarz J, Langer S, Nakanishi S, Frei E, Mack M: Riboflavin analogs as antiinfectives: occurrence, mode of action, metabolism and resistance. Curr Pharm Des 2013, 19: 2552-2560.
18. van der Westhuyzen R, Hammons JC, Meier JL, Dahesh S, Moolman WJ, Pelly SC, Nizet V, Burkart MD, Strauss E: The antibiotic CJ-15,801 is an antimetabolite that hijacks and then inhibits CoA biosynthesis. Chem Biol 2012, 19: 559-571.
19. Lee HH, Collins JJ: Microbial environments confound antibiotic efficacy. Nat Chem Biol 2011, 8: 6-9.
20. Cordero OX, Wildschutte H, Kirkup B, Proehl S, Ngo L, Hussain F, Le Roux F, Mincer T, Polz MF: Ecological populations of bacteria act as socially cohesive units of antibiotic production and resistance. Science 2012, 337: 1228-1231.
21. Raaijmakers JM, Mazzola M: Diversity and natural functions of antibiotics produced by beneficial and plant pathogenic bacteria. Annu Rev Phytopathol 2012, 50: 403-424.
22. Tegos GP, Haynes M, Strouse JJ, Khan MM, Bologa CG, Oprea TI, Sklar LA: Microbial efflux inhibition: tactics and strategies. Curr Pharmaceut Design 2011, 17: 1291-1302.
23. Fiamegos YC, Kastritis PL, Exarchou V, Han H, Bonvin AM, Vervoort J, Lewis K, Hamblin MR, Tegos GP: Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. PLoS ONE 2011, 6:e18127.
24. Kourtesi C, Ball AR, Huang YY, Jachak SM, Vera DM, Khondkar P, Gibbons S, Hamblin MR, Tegos GP: Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J 2013, 7: 34-52.
25. Choi H, Mascuch SJ, Villa FA, Byrum T, Teasdale ME, Smith JE, Preskitt LB, Rowley DC, Gerwick L, Gerwick WH: Honaucins A-C, potent inhibitors of inflammation and bacterial quorum sensing: synthetic derivatives and structure-activity relationships. Chem Biol 2012, 19: 589-598.
26. Jakobsen TH, van Gennip M, Phipps RK, Shanmugham MS, Christensen LD, Alhede M, Skindersoe ME, Rasmussen TB, Friedrich K, Uthe F, Jensen PØ, Moser C, Nielsen KF, Eberl L, Larsen TO, Tanner D, Høiby N, Bjarnsholt T, Givskov M: Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother 2012, 56: 2314-2325.
27. Keren I, Mulcahy LR, Lewis K: Persister eradication: lessons from the world of natural products. Methods Enzymol 2012, 517: 387-406.
28. Oldenburg M, Krüger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, Bathke B, Lauterbach H, Suter M, Dreher S, Koedel U, Akira S, Kawai T, Buer J, Wagner H, Bauer S, Hochrein H, Kirschning CJ: TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012, 337: 1111-1115.
29. Roux D, Pier GB, Skurnik D: Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes. J Antimicrob Chemother 2012, 67: 2785-2787.
30. Keatinge-Clay AT: The structures of type I polyketide synthases. Nat Prod Rep 2012, 29: 1050-1073.
31. Hur GH, Vickery CR, Burkart MD: Explorations of catalytic domains in non-ribosomal peptide synthetase enzymology. Nat Prod Rep 2012, 29: 1074-1098.
32. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA: Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 2013, 30: 108-160.
33. Tianero MD, Donia MS, Young TS, Schultz PG, Schmidt EW: Ribosomal route to small-molecule diversity. J Am Chem Soc 2012, 134: 418-425.
34. Knerr PJ, Oman TJ, Garcia de Gonzalo CV, Lupoli TJ, Walker S, van der Donk WA: Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation. ACS Chem Biol 2012, 7: 1791-1795.
35. Harvey CJ, Puglisi JD, Pande VS, Cane DE, Khosla C: Precursor directed biosynthesis of an orthogonally functional erythromycin analogue: selectivity in the ribosome macrolide binding pocket. J Am Chem Soc 2012, 134: 12259-12265.
36. Lucas X, Senger C, Erxleben A, Grüning BA, Döring K, Mosch J, Flemming S, Günther S, Günther S: StreptomeDB: a resource for natural compounds isolated from Streptomyces species. Nucleic Acids Res 2013, 41:D1130-D1136.
37. Wong WR, Oliver AG, Linington RG: Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. Chem Biol 2012, 19: 1483-1495.
38. Medema MH, Blin K, Cimermacic P, de Jager V, Zakrzewski P, Fischbach MA, Weber T, Takano E, Breitling R: antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. Nucleic Acids Res 2011, 39:W339-W346.
39. Liu G, Chater KF, Chandra G, Niu G, Tan H: Molecular regulation of antibiotic biosynthesis in Streptomyces. Microbiol Mol Biol Rev 2013, 77: 112-143.
40. Kallifidas D, Kang HS, Brady SF: Tetarimycin A, an MRSA-active antibiotic identified through induced expression of environmental DNA gene clusters. J Am Chem Soc 2012, 134: 19552-19555.
41. Feng Z, Chakraborty D, Dewell SB, Reddy BV, Brady SF: Environmental DNA-encoded antibiotics fasamycins A and B inhibit FabF in type II fatty acid biosynthesis. J Am Chem Soc 2012, 134: 2981-2987.
42. Engene N, Gunasekera SP, Gerwick WH, Paul VJ: Phylogenetic inferences reveal a large extent of novel biodiversity in chemically rich tropical marine cyanobacteria. Appl Environ Microbiol 2013, 79: 1882-1888.
43. Ziemert N, Podell S, Penn K, Badger JH, Allen E, Jensen PR: The natural product domain seeker NaPDoS: a phylogeny based bioinformatic tool to classify secondary metabolite gene diversity. PLoS ONE 2012, 7:e34064.
44. Qu X, Lei C, Liu W: Transcriptome mining of active biosynthetic pathways and their associated products in Streptomyces flaveolus. Ang Chem Int Engl 2011, 50: 9651-9654.
45. Evans BS, Ntai I, Chen Y, Robinson SJ, Kelleher NL: Proteomics- based discovery of koranimine, a cyclic imine natural product. J Am Chem Soc 2011, 133: 7316-7319.
46. Liu WT, Kersten RD, Yang YL, Moore BS, Dorrestein PC: Imaging mass spectrometry and genome mining via short sequence tagging identified the anti-infective agent arylomycin in Streptomyces roseosporus. J Am Chem Soc 2011, 133: 18010-18013.
47. Yuzawa S, Kim W, Katz L, Keasling JD: Heterologous production of polyketides by modular type I polyketide synthases in Escherichia coli. Curr Opin Biotechnol 2012, 23: 727-735.
48. Fu J, Bian X, Hu S, Wang H, Huang F, Seibert PM, Plaza A, Xia L, Müller R, Stewart AF, Zhang Y: Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting. Nat Biotechnol 2012, 30: 440-446.
49. Yuzawa S, Chiba N, Katz L, Keasling JD: Construction of a part of a 3-hydroxypropionate cycle for heterologous polyketide biosynthesis in Escherichia coli. Biochemistry 2012, 51: 9779-9781.